Premium
Magnetic resonance imaging of the efficacy of specific inhibition of 5α‐reductase in canine spontaneous benign prostatic hyperplasia
Author(s) -
Cohen S. M.,
Taber K. H.,
Malatesta P. F.,
Shpungin J.,
Berman C.,
Carlin J. R.,
Werrmann J. G.,
Prahalada S.,
Bryan R. N.,
Cordes E. H.
Publication year - 1991
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.1910210109
Subject(s) - finasteride , prostate , hyperplasia , dihydrotestosterone , urology , medicine , magnetic resonance imaging , 5 alpha reductase inhibitor , nuclear medicine , androgen , cancer , hormone , radiology
A leading role for prostatic levels of dihydrotestosterone (DHT) in the pathogenesis of benign prostatic hyperplasia is well established, if incompletely understood. The present study provides initial confirmation that 5α‐reductase inhibition alone is sufficient to prevent prostatic accumulation of DHT and to produce epithelial regression in the canine prostate. In dogs treated with the specific 5α‐reductase inhibitor finasteride, prostatic volume decreased to one‐third of the baseline volume, while the prostatic concentration of DHT fell fivefold: both were constant in placebo control dogs. Demonstration that MR imaging can serve as an accurate modality to assess prostatic volume was provided by serial measurements of the canine prostate and by correlation of the last imaging measurement with the weight of the excised prostate. Significant intensity changes were observed in T 2 ‐weighted images measured post‐treatment; these changes correlated with the histopathology of the prostate. These results suggest that beyond quantifying regression, multiecho T 2 measurements can be useful in probing accompanying changes occurring on the cellular level. © 1991 Academic Press, Inc.